Skip to main content

Table 2 Assessment of quality of evidence for outcomes using the GRADE

From: Correction: Effect of soy isoflavone supplementation on blood pressure: a meta-analysis of randomized controlled trials

 

Quality assessment

No. of patients

 

Quality of evidence

(GRADE)

Outcomes

No of studies

Study design

Risk of bias

Imprecision

Inconsistency

Indirectness

Publication bias

Intervention

Control

WMD (95%CI)

SBP

26

Randomized trials

No serious risk of bias a

No serious imprecision b

No serious inconsistency c

Serious indirectness d

No serious limitation e

1005

940

-1.40 (-2.65, -0.14)

Moderate

DBP

26

Randomized trials

No serious risk of bias

No serious imprecision

No serious inconsistency

Serious indirectness

No serious limitation

1005

940

-1.11 (-1.91, -0.30)

Moderate

  1. The quality of evidence was evaluated at 4 levels using GRADE (high, moderate, low, very low). a No downgrade for risk of bias, as most studies were assessed as low risk of bias. b No downgrade for imprecision, as the optimal information size was met and the 95%CI did not include the null value. c No downgrade for inconsistency, as there was a low of heterogeneity (SBP: I 2 = 0.0%, P = 0.61; DBP: I 2 = 0.0%, P = 0.87). d Downgraded for indirectness, as the intake of sodium and potassium was not provided, which may have confounding effects. e No downgrade for publication bias, as there was no publication bias evaluated by the funnel plots and Egger's test. Abbreviation: DBP diastolic blood pressure, SBP systolic blood pressure, GRADE Grading of Recommendations Assessment, Development and Evaluation, WMD weighted mean difference, 95% CI 95% confidence interval.